This Article Full Text Full Text (PDF) All Versions of this Article: 23/9/1667    most recent 01.ATV.0000087142.99472.F6v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Witherow, F. N. Articles by Newby, D. E. Search for Related Content PubMed PubMed Citation Articles by Witherow, F. N. Articles by Newby, D. E. Related Collections Health policy and outcome research Exercise/exercise testing/rehabilitation Acute coronary syndromes

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1667.)
© 2003 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Bradykinin Receptor Antagonism and Endothelial Tissue Plasminogen Activator Release in Humans

Fraser N. Witherow; Pamela Dawson; Christopher A. Ludlam; David J. Webb; Keith A.A. Fox; David E. Newby

From Cardiovascular Research (F.N.W., K.A.A.F., D.E.N.) and the Department of Haematology (P.D., C.A.L.), University of Edinburgh, Royal Infirmary of Edinburgh; and the Department of Clinical Pharmacology (D.J.W.), University of Edinburgh, Western General Hospital, Edinburgh, Scotland.

Correspondence to Dr David Newby, Cardiovascular Research, University of Edinburgh, Room SU314, Chancellor’s Bldg, 49 Little France Crescent, Little France, Edinburgh EH16 4SB, UK. E-mail d.e.newby{at}ed.ac.uk

Objective— We sought to assess pharmacodynamic responses to the bradykinin antagonist B9340 and to determine the contribution of the endothelial bradykinin receptor to stimulated tissue plasminogen activator (t-PA) release in humans.

Methods and Results— Bilateral forearm blood flow and plasma fibrinolytic variables were measured in 8 volunteers during 100 minutes of intrabrachial infusions of saline placebo, B9340 at 4.5 nmol/min, or B9340 at 13.5 nmol/min. On each occasion, intra-arterial bradykinin (30 to 3000 pmol/min) and substance P (4 to 16 pmol/min) were coinfused for 10 minutes at each dose. To assess the onset and offset of action, 6 additional subjects on 2 occasions received intra-arterial bradykinin (100 pmol/min) for 60 minutes with a coinfusion of either saline placebo or B9340 (13.5 nmol/min) for 12 minutes. During placebo infusion, bradykinin and substance P caused dose-dependent vasodilatation in the infused forearm (P<0.001). B9340 caused a dose-dependent inhibition of bradykinin-induced forearm vasodilatation and t-PA release (P<0.001) without affecting substance P–induced vasodilatation or t-PA release (P=NS). B9340 caused a reversible inhibition of bradykinin-induced vasodilatation (P<0.001) with a rapid onset and offset of action.

Conclusions— B9340 is a potent, reversible, and selective competitive receptor antagonist of bradykinin-induced vasodilatation and t-PA release in humans.

Key Words: bradykinin • blood flow • tissue plasminogen activator • receptor antagonism

This article has been cited by other articles:

				C. Giannarelli, A. Virdis, F. De Negri, A. Magagna, E. Duranti, A. Salvetti, and S. Taddei Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients Circulation, March 31, 2009; 119(12): 1625 - 1633. [Abstract] [Full Text] [PDF]

				W. S. Waring, J. A. McKnight, D. J. Webb, and S. R.J. Maxwell Uric Acid Restores Endothelial Function in Patients With Type 1 Diabetes and Regular Smokers Diabetes, November 1, 2006; 55(11): 3127 - 3132. [Abstract] [Full Text] [PDF]

				J. J. Oliver, D. J. Webb, and D. E. Newby Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2470 - 2479. [Abstract] [Full Text] [PDF]

				N. L.M. Cruden, F. N. Witherow, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1043 - 1048. [Abstract] [Full Text] [PDF]